Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: Saving for a rainy day

Pediatric Blood and Cancer

Volumn 46, Issue 7, 2006, Pages 719-722

  Grupp, Stephan A ^a   Cohn, Susan L ^b   Wall, Donna ^c   Reynolds, C Patrick ^d  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c TEXAS TRANSPLANT INSTITUTE   (United States)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Neuroblastoma; Stem cell transplantation; Stem cells

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CD34 ANTIGEN; ISOTRETINOIN;

CANCER CHEMOTHERAPY; CD34 SELECTION; CHILDHOOD CANCER; HIGH RISK PATIENT; HUMAN; INFUSION; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RELAPSE; REVIEW; STORAGE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTIGENS, CD34; BLOOD COMPONENT REMOVAL; CHILD; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRACTICE GUIDELINES; TISSUE PRESERVATION;

EID: 33646580355     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20769     Document Type: Review

References (28)

1. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165-1173.
2. Matthay KK, Harris R, Reynolds CP, et al. Improved event-free survival for autologous bone marrow transplantation vs chemotherapy in neuroblastoma: A Childrens Cancer Group study. Med Pediatr Oncol 1998;31:191-207.
3. Matthay KK. Impact of myeloablative therapy with bone marrow transplantation in advanced neuroblastoma. Bone Marrow Transplant 1996;18:S21-S24.
4. Matthay KK, O'Leary MC, Ramsay NK, et al. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: Review of recent Children's Cancer Group results. Eur J Cancer 1995;31A:572-575.
5. Seeger RC, Vo DD, Ugelstad J, Reynolds CP. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies and magnetic immunobeads. Prog Clin Biol Res 1986;211:285-293.
6. Grupp SA, Stern JW, Bunin N, et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 2000;18:2567-2575.
7. Kletzel M, Katzenstein HM, Haut PR, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: Results of the Chicago Pilot II Study. J Clin Oncol 2002;20:2284-2292.
8. Kessinger A, Armitage JO, Landmark JD, et al. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 1986;14:192-196.
9. Horowitz MM. Uses and growth of hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic Cell Transplantation, edn 2. Malden, MA: Blackwell; 1999. pp 12-32.
10. Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998;4:84-92.
11. Weaver CH, Potz J, Redmond J, et al. Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content. Bone Marrow Transplant 1997;19:1103-1110.
12. Stiff PJ. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 1999;23:S29-S33.
13. Gorlin JB, Vamvakes EC, Cooke E, et al. Large-volume leukapheresis in pediatric patients: Processing more blood diminishes the apparent magnitude of intra-apheresis recruitment. Transfusion 1996;36:879-885.
14. Gorlin JG, Humphries D, Kent P, et al. Pediatric large volume peripheral blood progenitor cell collections from patients under 25 kg: a primer. J Clin Apheresis 1996;11:195-203.
15. Grupp SA, Stern JW, Bunin N, et al. Rapid sequence tandem stem cell transplant for children with high-risk neuroblastoma. Med Pedialr Oncol 2000;35:696-700.
16. Howard JP, Maris JM, Kersun LS, et al. Tumor response and toxicity with multiple infusions of high dose 1311-M1BG for refractory neuroblastoma. Pediatr Blood Cancer 2005;44:232-239.
17. DuBois SG, Messina J, Maris JM, et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 2004;22:2452-2460.
18. Klingebiel T, Bader P, Bares R, et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A Pilot Study. Eur J Cancer 1998;34:1398-1402.
19. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002;20:2142-2149.
20. Anderson CP, Reynolds CP. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant 2002;30:135-140.
21. Anderson CP, Seeger RC, Satake N, et al. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J Pediatr Hematol Oncol 2001;23:500-505.
22. Keshelava N, Tsao-Wei D, Reynolds CP. Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53. Clin Cancer Res 2003;9:3492-3502.
23. Scheding S, Brugger W, Mertelsmann R, et al. Peripheral blood stem cells: In vivo biology and therapeutic potential. Stem Cells 1994;12:203-210; discussion 211.
24. Brugger W, Bross K, Frisch J, et al. Mobilisation of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyle-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood 1992;79:1193-1200.
25. Srinivasan R, Barrett J, Childs R. Allogeneic stem cell transplantation as immunotherapy for nonhematological cancers. Semin Oncol 2004;31:47-55.
26. Matthay KK, Seeger RC, Reynolds CP, et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: A report from the Childrens Cancer Group. J Clin Oncol 1994;12:2382-2389.
27. Philip T, Ladenstein R, Lasset C, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer 1997;33:2130-2135.
28. Reynolds CP. Detection and treatment of minimal residual disease in high-risk neuroblastoma. Pediatr Transplant 2004;8:56-66.